(Alliance News) - AstraZeneca PLC on Friday said that its investigational Covid long-acting antibody AZD3152 neutralises all known variants of concern.
The Cambridge-based pharmaceutical company said it will emphasise new data between Saturday and Tuesday at the European Congress of Clinical Microbiology & Infectious Diseases in Copenhagen, as well as data on its respiratory syncytial virus focused medicine Beyfortus.
Iskra Reic, Executive Vice President, Vaccines & Immune Therapies at AstraZeneca said: "Covid-19 remains of great concern and disproportionately impacts the immunocompromised. Our first in vitro data from our next generation long-acting antibody, AZD3152, show its potential to provide protection to the immunocompromised from all known Covid-19 variants of concern to date."
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Astrazeneca (AZN)
